Wang Peng, Chen Weixiong, Ma Tongtong, Lin Zhaoyu, Liu Chongbin, Liu Youhua, Hou Fan Fan
Division of Nephrology, Nanfang Hospital, Southern Medical University, State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Guangzhou 510515, China.
Department of Stomatology, Longgang District Central Hospital, Affiliated to Guangzhou University of Traditional Chinese Medicine, Shenzhen, Guangdong 518116, China.
Mol Ther Nucleic Acids. 2020 Aug 5;22:1-16. doi: 10.1016/j.omtn.2020.08.003.
The transforming growth factor-β (TGF-β)/Smads signal plays an important role in cancer metastasis by mediating the epithelial-mesenchymal transition (EMT) in cancer cells. lnc-TSI is a recently identified long noncoding RNA that negatively regulates the TGF-β/Smads signal. The present study was conducted to test the hypothesis that lnc-TSI inhibits metastasis in clear cell renal cell carcinoma (ccRCC) by regulating the TGF-β/Smad3 pathway. Herein, we show that lnc-TSI was upregulated in ccRCC cells and tissue and was associated with activation of the TGF-β/Smads signal. Depleting lnc-TSI enhanced tumor cell invasion and metastasis in vitro and ccRCC lung metastasis in vivo, whereas overexpressing lnc-TSI inhibited ccRCC cell invasion and tumor metastasis. Mechanistic studies indicated that lnc-TSI specifically inhibited the phosphorylation of Smad3 and subsequent EMT by binding with the MH2 domain of Smad3 to block the interaction between Smad3 and TGF-β receptor I in ccRCC cells. In a cohort of 150 patients with ccRCC, expression of lnc-TSI in tumors was negatively correlated with phosphorylated (p)Smad3 and activated EMT markers. Patients with expression of tumor lnc-TSI greater than or equal to the median at radical nephrectomy had a higher survival rate compared to those with lnc-TSI below the median during follow-up. These findings reveal a new regulatory mechanism of ccRCC metastasis and suggest a potential molecular target for the development of anti-cancer drugs.
转化生长因子-β(TGF-β)/Smads信号通过介导癌细胞的上皮-间质转化(EMT)在癌症转移中发挥重要作用。lnc-TSI是最近鉴定出的一种长链非编码RNA,它对TGF-β/Smads信号起负调节作用。本研究旨在验证lnc-TSI通过调节TGF-β/Smad3信号通路抑制透明细胞肾细胞癌(ccRCC)转移的假说。在此,我们发现lnc-TSI在ccRCC细胞和组织中上调,并与TGF-β/Smads信号的激活相关。敲低lnc-TSI可增强体外肿瘤细胞的侵袭和转移以及体内ccRCC的肺转移,而lnc-TSI过表达则抑制ccRCC细胞的侵袭和肿瘤转移。机制研究表明,lnc-TSI通过与Smad3的MH2结构域结合,特异性抑制Smad3的磷酸化及随后的EMT,从而阻断ccRCC细胞中Smad3与TGF-β受体I之间的相互作用。在150例ccRCC患者队列中,肿瘤中lnc-TSI的表达与磷酸化(p)Smad3及激活的EMT标志物呈负相关。在根治性肾切除术中肿瘤lnc-TSI表达大于或等于中位数的患者,与随访期间lnc-TSI低于中位数的患者相比,生存率更高。这些发现揭示了ccRCC转移的一种新调控机制,并提示了一种潜在的抗癌药物开发分子靶点。